Welcome to our dedicated page for Positron news (Ticker: POSC), a resource for investors and traders seeking the latest updates and insights on Positron stock.
Positron Corporation (POSC) is a molecular imaging medical device company focused on PET and PET-CT imaging systems and clinical services for nuclear medicine providers across North America. The POSC news page on Stock Titan aggregates company announcements, transaction updates, and other disclosures that illustrate how Positron is executing its strategy in cardiac and oncology imaging.
Investors and healthcare professionals following POSC news can review releases on capital raises, such as equity financings used to support commercial expansion, product development, and regulatory initiatives. The company also issues news on its SEC reporting status, including the filing of a Form 10 registration statement and related steps toward operating as a reporting company under the Securities Exchange Act of 1934.
Another major category of Positron news involves product and sales activity. Recent announcements describe sales and agreements for Attrius PET and NeuSight PET-CT 64-slice scanners, multi-unit PET-CT orders, and placements through programs such as the NeuSight Prime Rental Program with cardiovascular diagnostic and treatment practices. These updates provide insight into demand for Positron’s cardiac PET and PET-CT systems among nuclear cardiology and nuclear medicine groups.
Positron also reports on strategic partnerships and corporate developments, including its industry partnership with MedAxiom, establishment of a new headquarters in the Buffalo–Niagara Falls region, and technology collaboration with Shenyang Intelligent Neuclear Technology Co., a subsidiary of Neusoft Medical Systems. By reviewing the POSC news feed, readers can track how the company is positioning its PET and PET-CT technologies, expanding relationships in cardiovascular care, and supporting adoption of cardiac PET imaging in clinical practice.
For ongoing research into POSC stock and business progress, users can return regularly to this page to see the latest company-issued news items and related market updates.
Positron Corporation (OTC: POSC) announced a $2.0 million capital raise on Dec. 30, 2025, issuing 1,333,333 shares in exchange for the proceeds.
The company said the funds will be used to accelerate commercial expansion, advance product development and regulatory activities, pursue new markets, and support increased placements of cardiac PET and PET-CT systems.
Management described the financing as strengthening the balance sheet to support near-term growth initiatives and longer-term opportunities in new products, markets, clinical services, and technology development.
Positron Corporation (OTC: POSC) announced on November 17, 2025 that it has become an SEC reporting company by filing a Form 10 containing required financial statements and disclosures.
The company will now file quarterly, annual, and current reports under the Securities Exchange Act of 1934, enhancing financial transparency, strengthening corporate governance, and positioning Positron to pursue an uplisting to a senior exchange. Management said the change supports broader institutional visibility and access to capital as Positron commercializes its PET-CT technologies, including a new 4D PET-CT system, and leverages an exclusive North American partnership with Neusoft Medical Systems.
Positron Corporation (OTC: POSC), a molecular imaging technology company specializing in PET and PET-CT systems, has announced a strategic partnership with MedAxiom, a leading cardiovascular performance solutions provider.
The partnership connects Positron with MedAxiom's extensive network of cardiovascular organizations, physicians, and thought leaders. This collaboration will provide Positron with market intelligence, clinical insights, and collaboration opportunities to support broader adoption of PET-CT technology in cardiovascular care.
MedAxiom's Executive VP Joe Sasson highlighted the rapid growth of Cardiac PET in transforming cardiovascular care, while Positron's President Adel Abdullah emphasized the partnership's potential to expand their user base and accelerate adoption of their imaging solutions.
Positron Corporation (OTC: POSC) has been awarded the Innovation Award in the PET-CT Imaging category at the 2025 Medical Device Network Excellence Awards. The company's PET-CT 64 Slice system stands out as the most cost-effective PET-CT system in the US, making advanced hybrid imaging more accessible to smaller clinics and community hospitals.
The system offers significant advantages including enhanced workflow efficiency with capability to perform up to 20+ exams daily, flexible rental packages, and comprehensive clinical applications across cardiac, oncology, and neurology imaging. Positron plans to launch its advanced Affinity 4D PET-CT system in Q4 2025, featuring LYSO crystal technology, AI-enhanced motion monitoring, and improved dose reduction techniques.
Positron Corporation (OTC: POSC), a molecular imaging technology leader, has announced two strategic corporate developments. The company has established a new corporate headquarters in the Buffalo-Niagara Falls region under a long-term lease, which will serve as their corporate operations hub, product showroom, and testing center.
Additionally, Positron's Board of Directors has approved the company's redomiciling from Texas to Delaware. This move aims to enhance corporate governance and legal framework as the company prepares to file a Form 10 registration statement with the SEC to become a fully reporting public company.
Positron Corporation (OTC: POSC) has secured a significant sale of four PET-CT 64-slice scanners to a leading nuclear cardiology group. The company's next-generation imaging systems feature a 72 cm wide-bore gantry, high-sensitivity detectors with reduced radiation exposure, and the smallest footprint in its class.
The PET-CT scanners deliver high-resolution anatomic and functional imaging for both cardiac and oncology applications, offering enhanced diagnostic capabilities from myocardial perfusion to tumor detection. The deal highlights growing market acceptance of Positron's advanced imaging technology and comprehensive support services.
Positron Corporation (OTC: POSC) has announced the sale of its NeuSight PET-CT 64-slice scanner to a prominent nuclear cardiologist. The NeuSight PET-CT scanner features a 72 cm gantry and high-sensitivity acquisition technology that reduces radiation exposure. The system, which has the smallest footprint in its class, is designed for both cardiology and oncology applications, offering anatomic and functional imaging capabilities.
The scanner supports various studies, including cardiac, tumor, and neurological imaging. According to President Adel Abdullah, this sale to a key opinion leader (KOL) of a larger medical group represents a potential gateway to broader organizational opportunities as Positron expands into the western U.S. market.
Positron (OTC: POSC) has announced the sale of four PET-CT scanners to a prominent cardiovascular diagnostics provider. The company's molecular imaging systems feature a 72 cm gantry and high-sensitivity acquisition technology, reducing radiation exposure while maintaining compact design.
The PET-CT systems are engineered for both cardiology and oncology applications, offering advanced data acquisition capabilities for faster and more precise scans. Key features include the smallest footprint in their class, versatility for cardiac and tumor imaging, and brain studies capabilities.
According to Adel Abdullah, President of Positron, this sale reflects growing demand for cardiac PET imaging. The company aims to make PET technology more accessible through cost-effective solutions and comprehensive support services.
Positron (POSC) has secured an $8 million equity investment through the sale of 8 million common shares to two strategic investors. The capital will fund the company's expansion in the PET-CT imaging market, particularly in nuclear cardiology and oncology.
The funding will support multiple strategic initiatives, including:
- Enhanced sales and marketing efforts
- Expansion of sales personnel
- Product development and offerings
- Strengthening industry partnerships
- Market expansion in North America and Europe
The company plans to use this capital to resume SEC filings and pursue an uplisting to a senior stock exchange. According to President Adel Abdullah, this investment positions Positron to capitalize on increasing PET-CT imaging adoption and develop a competitive edge in the marketplace.
Positron (OTC: POSC) has secured an agreement for three NeuSight PET-CT 64-slice scanners under its Prime Rental Program with a leading cardiovascular practice. The NeuSight PET-CT features a 72 cm gantry and high-sensitivity acquisition technology, offering reduced radiation exposure and superior imaging capabilities.
The system boasts the smallest footprint among PET-CT systems and excels in both cardiology and oncology studies. Key features include advanced data acquisition technology for faster and more precise scans, supporting various molecular imaging applications including heart, tumor, and brain studies.
FAQ
What is the current stock price of Positron (POSC)?
What is the market cap of Positron (POSC)?
